You have 1 action to finish to complete your account. Customize your experience by selecting your interests on the Personalization page

No matches

24 search results for: standard of care

GINA-Based Opportunities for Improved Outcomes With Effective Management <b>of</b> Pediatric Asthma in Children 6-11 Years <b>of</b> Age

interactivity

GINA-Based Opportunities for Improved Outcomes With Effective Management of Pediatric Asthma in Children 6-11 Years of Age

5 min

Pulmonology

Explore GINA-based recommendations for identifying risk factors, optimizing management plans, and monitoring disease progression in pediatric asthma.

interactivity

Eosinophilic Esophagitis (EoE) Pediatric Interactive Patient Case

8 min

Gastroenterology

Experience a pediatric patient's journey from infancy to adolescence with guideline-based learnings on EoE diagnosis, treatment, and long-term care.

Comparative Efficacy <b>of</b> Biologics for Patients with Uncontrolled and/or Severe CRSwNP

expert video

Comparative Efficacy of Biologics for Patients with Uncontrolled and/or Severe CRSwNP

7 min

Rhinology

Prof. Peter Hellings presents the comparative efficacy of biologics for patients with uncontrolled and/or severe CRSwNP.

IRS-ISIAN 2024 | Mechanisms <b>of</b> Smell Loss in CRSwNP: Blockage and Inflammation

expert video

IRS-ISIAN 2024 | Mechanisms of Smell Loss in CRSwNP: Blockage and Inflammation

10 min

Rhinology

Prof. Joaquim Mullol examines the mechanisms of smell loss in CRSwNP including the roles of conductive and sensorineural dysfunction.

IRS-ISIAN 2024 | The Importance <b>of</b> Understanding Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Importance of Understanding Smell Loss and Congestion in CRSwNP

30 min

Rhinology

Prof. Joaquim Mullol presents on the proposed mechanisms of smell loss and nasal congestion in CRSwNP.

IRS-ISIAN 2024 | The Underappreciated Burden <b>of</b> Smell Loss and Congestion in CRSwNP

expert video

IRS-ISIAN 2024 | The Underappreciated Burden of Smell Loss and Congestion in CRSwNP

7 min

Rhinology

Prof. Joaquim Mullol describes the burdens of smell loss and nasal congestion for patients with uncontrolled and/or severe CRSwNP.

Implementation <b>of</b> Guidelines into Daily Practice: Past, Present, and Future

expert video

Implementation of Guidelines into Daily Practice: Past, Present, and Future

10 min

Rhinology

Dr. Stella Lee explores the past, present and future implementation of guidelines into daily practice.

Clinical Management <b>of</b> CRSwNP: Maximizing Symptom Improvement

expert video

Clinical Management of CRSwNP: Maximizing Symptom Improvement

17 min

Rhinology

Prof. Fokkens presents recent evidence of biologic effectiveness for CRSwNP from the real-world setting

expert video

IRS-ISIAN 2024 | Emerging Expert Definitions of Remission in CRSwNP

3 min

Rhinology

Prof. Peter Hellings highlights the EPOS/EUFOREA 2024 definition of remission and calls for an elevation of treatment goals in CRSwNP.

IRS-ISIAN 2024 | Guideline Definitions <b>of</b> Control in CRSwNP

expert video

IRS-ISIAN 2024 | Guideline Definitions of Control in CRSwNP

5 min

Rhinology

Prof. Peter Hellings explores the concept of disease control in CRSwNP.

The Prevalence and Burden <b>of</b> Type 2 Inflammation in Patients With CRSwNP

expert video

The Prevalence and Burden of Type 2 Inflammation in Patients With CRSwNP

8 min

Rhinology

Dr. Stella Lee educates on the immune responses mediating CRSwNP and the prevalence of type 2 inflammation.

expert video

UEGW 2024 | WHY Is Long-Term Management of EoE Important?

10 min

Gastroenterology

Prof. Salvatore Oliva discusses the impact of chronic type 2 inflammation on EoE progression, highlighting the need for long-term management.

ADVENT is a global medical education non-promotional program by Sanofi and Regeneron. This website is intended only for duly authenticated healthcare professionals in Algeria, Argentina, Australia, Austria, Bahrain, Belgium, Brazil, Bulgaria, Canada, Chile, China, Colombia, Costa Rica, Croatia, Czech Republic, Denmark, Dominican Republic, Ecuador, Egypt, Estonia, Finland, France, Germany, Greece, Guatemala, Hong Kong, Hungary, Iceland, India, Israel, Italy, Japan, Kuwait, Latvia, Lebanon, Lithuania, Macau, Malaysia, Norway, Oman, Panama, Peru, Poland, Portugal, Qatar, Romania, Saudi Arabia, Singapore, Slovenia, South Africa, South Korea, Spain, Sudan, Sweden, Switzerland, Taiwan, Thailand, The Netherlands, Turkey, United Arab Emirates, or the United States of America.

For healthcare professionals in Algeria: Please read the additional Terms of Use.

Sanofi and Regeneron are global leaders in pharmaceutical development, each with a long history of supporting frontline physicians to improve human health and reduce the burden of disease. Driven by the same commitment to patients and their families, Sanofi and Regeneron have partnered to take on type 2 inflammation and the range of chronic conditions in which excessive inflammation plays a role.

Country/region: Hong KongChange country/region